Next-Generation Nanobody Targeting EGFR and Integrin Receptor for Digestive-Gastrointestinal Cancer Therapy

VHH-P850 is an innovative humanized single-domain antibody program currently in the Biological Testing stage, designed to target both epidermal growth factor receptor (EGFR) and Integrin Receptor. By fusing advanced targeting elements, VHH-P850 holds promise for the treatment of Digestive-gastrointestinal Cancer. This construct leverages precise molecular recognition to block critical tumorigenic pathways. Developed with robust expression in E. coli BL21, VHH-P850 represents a new therapeutic modality aiming to address the substantial unmet needs in gastrointestinal oncology by targeting EGFR and Integrin Receptor with high specificity and adaptability.

Licensing Opportunity

VHH-P850 is available for out-licensing and collaborative partnerships. We invite pharmaceutical and biotechnology companies to explore opportunities to co-develop and advance this promising gastrointestinal cancer therapeutic program.

Development Phase

Modality

VHH-P850 is a single-domain nanobody that targets EGFR and Integrin Receptor, fused to the tumor-penetrating iRGD peptide via a flexible GGGGSGGGGSGGGGS linker. This modular design combines the advantages of nanobodies—such as small molecular size, superior tissue penetration, and high stability—with the tumor homing capability of iRGD. Expressed in E. coli BL21, VHH-P850’s structure enables efficient production and scalability. For gastrointestinal cancer, these features facilitate effective targeting of tumor cells within dense tissue environments, supporting improved biodistribution and therapeutic efficacy compared to conventional antibody modalities.

Target

EGFR and Integrin Receptor are key membrane-associated proteins involved in signal transduction, cell adhesion, and proliferation. EGFR is frequently overexpressed in various epithelial-derived tumors, including those of the gastrointestinal tract, while Integrin Receptor facilitates tumor cell interaction with the extracellular matrix and promotes metastasis. Both EGFR and Integrin Receptor are predominantly expressed on malignant epithelial and stromal cells in gastrointestinal cancer. Their dysregulation drives oncogenic signaling, tumor progression, and therapeutic resistance. Targeting EGFR and Integrin Receptor disrupts critical pathways for cancer cell survival and invasion. VHH-P850’s concurrent targeting of EGFR and Integrin Receptor is strategically positioned to inhibit multiple cancer-promoting mechanisms, enhancing therapeutic potential and differentiation in the competitive oncology landscape.

Mechanism of Action

VHH-P850 exerts its biological effects by binding to EGFR and Integrin Receptor on the surface of gastrointestinal cancer cells. By interfering with EGFR-mediated signal transduction, VHH-P850 can disrupt downstream proliferative and survival pathways critical to tumor growth. Concurrently, engagement of Integrin Receptor impairs tumor cell adhesion and migration, potentially hindering metastasis. The addition of the iRGD peptide further augments tumor penetration, facilitating deeper therapeutic access to malignant tissues. As a nanobody platform, VHH-P850 also offers opportunities for development into antibody-drug conjugates (ADCs), bispecific constructs, or targeted delivery vehicles, addressing a range of therapeutic strategies for gastrointestinal oncology.

Digestive-gastrointestinal Cancer

Gastrointestinal cancers encompass malignancies of the esophagus, stomach, pancreas, liver, biliary tract, and colorectal region. These cancers collectively contribute to a substantial global morbidity and remain a leading cause of cancer mortality. The standard of care often includes surgery, radiotherapy, chemotherapy, and targeted therapy. Despite advances, conventional strategies frequently face challenges such as late diagnosis, limited responsiveness, systemic toxicity, and emerging resistance to existing targeted agents. Important molecular alterations, including aberrant activation of EGFR and Integrin Receptor pathways, are prevalent in gastrointestinal tumors and are associated with aggressive disease and poor prognosis. The medical community continues to seek novel therapeutic modalities that combine precision targeting with enhanced tumor penetration and minimized off-target effects. VHH-P850, with its dual specificity for EGFR and Integrin Receptor, tumor-penetrating capacity, and nanobody-based bioengineering, represents a promising strategy to overcome current treatment limitations and address critical unmet needs in digestive-gastrointestinal cancer management.